质子泵抑制剂联合氯吡格雷在心血管疾病治疗中的研究进展

抗血小板药物可有效减少血栓事件的发生，但增加胃肠道出血风险，通常加用质子泵抑制剂（PPI）来避免抗血小板药物所导致的黏膜损害。PPI具有与氯吡格雷相同的肝脏的代谢途径，可能降低氯吡格雷的抗血小板疗效并导致发生不良心血管事件的危险增加。氯吡格雷与PPI联合应用是否影响抗血小板药物治疗效果，目前对这一现象尚无定论，该文就氯吡格雷与PPI相互作用的机制和临床研究进展作一综述。

Advances in clinical research of combined clopidogrel and proton pump inhibitors in patients with cardiovascniar disease

Antiplatelet agents can effectively decrease the thromboembolic events, but increase the risk of gastrointestinal bleeding due to mueosal damage, therefore antiplatelet agents are commonly used with proton pump inhibitors （PPI） to reduce the risk; as they shared the same metabolie pathway in the liver, recent studies show that treatment with elopidogrel plus PPIs can increase the incidence of adverse cardiovascular events. Despite being con- troversial, this finding has attracted wide attention from clinicians. This article will review the recent advances in clinical research on the interaction between PPI and clopidogrel.